Skip to main content

Peer Review reports

From: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Original Submission
26 Dec 2014 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Author responded Author comments
Resubmission - Version 6
Submitted Manuscript version 6
Author responded Author comments
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
16 Nov 2015 Editorially accepted
1 Dec 2015 Article published 10.1186/s12885-015-1936-z

You can find further information about peer review here.

Back to article page
\